Skip to content
Today we will run through one way of estimating the intrinsic value of Northrop Grumman Corporation (NYSE:NOC) by......
Distillate Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Distillate Capital’s U.S. Fundamental Stability & Value (U.S. FSV) strategy's year-to-date decline of 1.19% through Q2 2020, is ahead of the comparable drop of 3.08% for the S&P 500 and 15.1 percentage points above the -16.3% return […]...
Distillate Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Distillate Capital’s U.S. Fundamental Stability & Value (U.S. FSV) strategy's year-to-date decline of 1.19% through Q2 2020, is ahead of the comparable drop of 3.08% for the S&P 500 and 15.1 percentage points above the -16.3% return […]...
Occidental Petroleum Corporation (NYSE:OXY) shareholders will doubtless be very grateful to see the share price up 41......
The recent surge of COVID-19 cases has put reopening targets on hold for many U.S. companies, such as Walt Disney Co (NYSE: DIS). On Thursday, one Disney analyst ran out of patience.The Disney Analyst: Cowen analyst Doug Creutz downgraded Disney from Outperform to Market Perform and cut his price target from $101 to $97.The Disney Thesis: Creutz said Disney's Parks and Film segments will likely be shut down longer than previously anticipated based on the latest coronavirus trends. Disney has a large Park presence in Florida, and its movie business is in California, two of the hardest-hit states by the recent second wave of cases.Creutz previously forecast an easing of social distancing restrictions by the end of 2020, but he now expects social distancing requirements will be extended until at least mid-2021.Even after restrictions are lifted, Creutz said Disney's Parks business will likely be slow to recover. He projects Disney's domestic...
With the public desperate for a solution to COVID-19, Moderna’s (MRNA) status has increased to such an extent that any good news coming out of its HQ ripples across the whole market. Moderna can take partial credit for the S&P 500’s uptick on Wednesday, following news of the positive development in its COVID-19 vaccine program.A study published in the New England Journal of Medicine showed that in the Phase 1 study of the biotech’s experimental vaccine mRNA-1273, all 45 patients produced antibodies to the coronavirus.Moreover, participants who received two 100-microgram doses of the vaccine (patients were given either 250, 100, or 25 micrograms) produced antibody levels more than twice than those of people who had recovered from COVID-19. Antibodies are key in preventing the virus’ infection.The good news sent Moderna shares rising again. Over the past week the stock is up by over 31% and overall, by 315% year-to-date.While the data...
Yahoo Finance's Jared Blikre breaks down some of the features of the Yahoo Finance Premium package.
...
